Ben McCullough, 76, received an EVOQUE heart valve last fall. On Wednesday, he got to thank the makers face-to-face.

For years, Mertz, a great-grandmother from Essex, struggled with worsening symptoms of tricuspid valve regurgitation, a condition in which blood leaks backward into the heart. She found simple ...

Another prespecified outcome of the trial, 2-year freedom from all-cause mortality, tricuspid valve surgery ... and 55% had New York Heart Association class III/IV symptoms.

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

Citation: Minimally invasive valve repair reduces heart failure hospitalizations in patients with severe tricuspid regurgitation (2025, March 31) retrieved 4 April 2025 from https://medicalxpress ...

Transcatheter tricuspid valve replacement has been gaining momentum in heart centers across the U.S. Chicago-based Northwestern Medicine cardiologists have performed at least 100 TTVR procedures ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

system to treat tricuspid regurgitation (TR), or a leaky heart valve, offers substantial and sustained improvements in the severity of TR after two years. The results also demonstrate the TriClip ...

The funding will be put towards an early feasibility study, designed to determine the clinical effectiveness and safety of Laplace’s transcatheter tricuspid ... open-heart valve surgical ...

The primary endpoint was a composite of all-cause mortality or tricuspid valve surgery, heart failure hospitalizations, and quality-of-life improvement measured by the KCCQ score. TriClip is ...